Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 37 points (0.2%) at 16,943 as of Wednesday, July 9, 2014, 12:45 PM ET. The NYSE advances/declines ratio sits at 1,468 issues advancing vs. 1,471 declining with 161 unchanged. The Health Services industry currently is unchanged today versus the S&P 500, which is up 0.3%. A company within the industry that fell today was Agilent Technologies ( A), up 0.7%. Top gainers within the industry include Opko Health ( OPK), up 2.3%, Cooper Companies ( COO), up 1.7%, Universal Health Services ( UHS), up 0.7%, Edwards Lifesciences ( EW), up 0.7% and Smith & Nephew ( SNN), up 0.6%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Covance ( CVD) is one of the companies pushing the Health Services industry lower today. As of noon trading, Covance is down $1.06 (-1.2%) to $84.92 on average volume. Thus far, 246,159 shares of Covance exchanged hands as compared to its average daily volume of 567,100 shares. The stock has ranged in price between $84.64-$86.24 after having opened the day at $85.96 as compared to the previous trading day's close of $85.98. Covance Inc., a drug development services company, provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries worldwide. It operates in two segments, Early Development and Late-Stage Development. Covance has a market cap of $5.0 billion and is part of the health care sector. Shares are down 2.4% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Covance a buy, 1 analyst rates it a sell, and 5 rate it a hold. TheStreet Ratings rates Covance as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, growth in earnings per share and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covance Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.